ADC Therapeutics SA (ADCT) Tops Q1 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq hits record high as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mail
Get Alerts ADCT Hot Sheet
Join SI Premium – FREE
ADC Therapeutics SA (NYSE: ADCT) reported Q1 EPS of ($0.22), $0.18 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $23.03 million versus the consensus estimate of $17.89 million.
For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs sees AI investment adding to European growth in 2026
- Lion Copper Corp. adds CEO John Banning to its board of directors
- Alethia Capital Starts TTM Technologies (TTMI) at Overweight, 'A Unique Proxy Standing for USA PCB'
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
